Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 186

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Farlow, Martin R., Salloway, Stephen, Tariot, Pierre N., Yardley, Jane, Moline, Margaret L., Wang, Qin, Brand-Schieber, Elimor, Zou, Heng, Hsu, Timothy, Satlin, Andrew · 2010 · Clinical Therapeutics

Abstract

Background Currently approved Alzheimer’s disease (AD) treatments have been reported to provide symptomatic benefit, without proven impact on clinical progression. We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor. Objective The aim of this study was to determine the effectiveness and tolerability of increasing donepezil from 10 to 23 mg/d in patients with moderate to severe AD. Methods This randomized, double-blind study was conducted at 219 sites in Asia, Europe, Australia, North America, South Africa, and South America from June 6, 2007, to March 27, 2009. Patients aged 45 to 90 years with probable AD, Mini-Mental State Examination score 0 to 20 (moderate to severe impairment), and who were receiving donepezil 10 mg once daily for ≥12 weeks before the start of the study were eligible. Patients (n = 1467) were randomly assigned to receive high-dose donepezil (23 mg once daily) or standard-dose donepezil (10 mg once daily) for 24 weeks. Coprimary effectiveness measures were changes in cognition and global functioning, as assessed using least squares mean changes from baseline (LSM [SE] Δ) scores (last observation carried forward) on the Severe Impairment Battery (SIB; cognition) and the Clinician’s Interview-Based Impression of Change Plus Caregiver Input scale (CIBIC+; global function rating) overall change score (mean [SD]) at week 24. Treatment-emergent adverse events (TEAEs) were assessed using spontaneous patient/caregiver reporting and open-ended questioning; clinical laboratory testing (hematology, biochemistry, and urinalysis panels analyzed by a central laboratory); 12-lead ECG; and physical and neurologic examinations, including vital sign measurements. Results The effectiveness analyses included 1371 patients (mean age, 73.8 years; 62.8% female; 73.5% white; weight range, 34.0–138.7 kg). A total of 296 of 981 patients (30.2%) withdrew from the donepezil 23-mg/d group; 87 of 486 patients (17.9%) withdrew from the donepezil 10-mg/d group. At study end (week 24), the LSM (SE) Δ in SIB score was significantly greater with donepezil 23 mg/d than with donepezil 10 mg/d (+2.6 [0.58] vs +0.4 [0.66], respectively; difference, 2.2; P < 0.001). The between-treatment difference in CIBIC+ score was nonsignificant (4.23 [1.07] vs 4.29 [1.07]). In post hoc analysis, LSM Δ in SIB score and CIBIC+ treatment effect at end point were greater with donepezil 23 mg/d than 10 mg/d in patients with more advanced AD compared with less impaired patients (SIB, +1.6 [0.78] vs −1.5 [0.88], respectively [P < 0.001]; CIBIC+, 4.31 [1.09] vs 4.42 [1.10] [P = 0.028]). TEAEs were reported in 710 of 963 patients (73.7%) who received donepezil 23 mg/d and in 300 of 471 patients (63.7%) who received donepezil 10 mg/d. With donepezil 23 mg/d, mild, moderate, and severe TEAEs were reported in 297 (30.8%), 332 (34.5%), and 81 (8.4%) patients, respectively; with donepezil 10 mg/d, these proportions were 147 (31.2%), 119 (25.3%), and 34 (7.2%). The 3 most common severe AEs reported with the 23-mg/d dose were nausea (9 patients [0.9%] vs 1 [0.2%] with the 10-mg/d dose), dizziness (7 [0.7%] vs 1 [0.2%]), and vomiting (6 [0.6%] vs 0). The most commonly reported TEAEs considered probably related to treatment with the 23-mg/d dose were nausea (59 patients [6.1%] vs 9 [1.9%] with the 10-mg/d dose), vomiting (48 [5.0%] vs 4 [0.8%]), and diarrhea (31 [3.2%] vs 7 [1.5%]). Thirteen deaths were reported during the study or within 30 days of study discontinuation (23 mg/d, 8 patients [0.8%]; 10 mg/d, 5 patients [1.1%]); all were considered unrelated to the study medication. Conclusions In this study in patients with moderate to severe AD, donepezil 23 mg/d was associated with greater benefits in cognition compared with donepezil 10 mg/d. The between-treatment difference in global functioning was not significant in the overall population. Patients with more advanced AD appeared to benefit from donepezil 23 mg/d on the assessment of global functioning, but this observation requires additional studies for confirmation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clinthera.2010.06.019

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 32

  1. Reisberg, 1997, Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association, Int Psychogeriatr., 9, 11, 10.1017/S1041610297004675 · DOI
  2. Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial, JAMA, 291, 317, 10.1001/jama.291.3.317 · DOI · Paper page
  3. Feldman, 2001, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published correction appears in Neurology. 2001;57:2153], Neurology., 57, 613, 10.1212/WNL.57.4.613 · DOI · Paper page
  4. Geldmacher, 2006, Realistic expectations for treatment success in Alzheimer's disease, J Nutr Health Aging., 10, 417
  5. Winblad, 2006, Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study [published corrections appear in Lancet. 2006;386:1650 and Lancet. 2006;367: 1980], Lancet., 367, 1057, 10.1016/S0140-6736(06)68350-5 · DOI · Paper page
  6. Xiong, 2005, Combination drug therapy for Alzheimer's disease: What is evidence-based, and what is not?, Geriatrics., 60, 22
  7. Tariot, 2008, Combination therapies for treating Alzheimer's disease, US Neurology., 4, 31, 10.17925/USN.2008.04.01.31 · doi:10.17925/usn.2008.04.01.31
  8. Mesulam, 2004, The cholinergic lesion of Alzheimer's disease: Pivotal factor or side show?, Learn Mem., 11, 43, 10.1101/lm.69204 · DOI · Paper page
  9. Pappas, 2000, Choline acetyltrans-ferase activity and cognitive domain scores of Alzheimer's patients, Neurobiol Aging., 21, 11, 10.1016/S0197-4580(00)00090-7 · DOI
  10. Imbimbo, 2001, Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease, CNS Drugs., 15, 375, 10.2165/00023210-200115050-00004 · DOI
  11. Kuhl, 2000, Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex, Ann Neurol., 48, 391, 10.1002/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H · DOI
  12. Bohnen, 2005, Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease, J Neurol Neurosurg Psychiatry., 76, 315, 10.1136/jnnp.2004.038729 · DOI · Paper page
  13. Folstein, 1975, “Mini-mental state” A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res., 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  14. Nozawa, 2009, Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan, Psychogeriatrics., 9, 50, 10.1111/j.1479-8301.2009.00291.x · DOI
  15. Farlow, 2005, Moderate to severe Alzheimer disease: Definition and clinical relevance, Neurology., 65, S1, 10.1212/WNL.65.6_suppl_3.S1 · DOI
  16. McKhann, 1984, Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology., 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  17. Panisset, 1994, Severe impairment battery. A neuropsychological test for severely demented patients, Arch Neurol., 51, 41, 10.1001/archneur.1994.00540130067012 · DOI · Paper page
  18. Schmitt, 1997, The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study, Alzheimer Dis Assoc Disord., 11, S51, 10.1097/00002093-199700112-00008 · DOI
  19. Alexopoulos, 1988, Cornell Scale for Depression in Dementia, Biol Psychiatry., 23, 271, 10.1016/0006-3223(88)90038-8 · DOI · Paper page
  20. Radloff, 1977, The CES-D Scale: A Self-Report Depression Scale for Research in the General Population, Appl Psychol Meas., 1, 385, 10.1177/014662167700100306 · DOI · Paper page
  21. Joffres, 2000, Qualitative analysis of the clinician interview-based impression of change (Plus): Methodological issues and implications for clinical research, Int Psychogeriatr., 12, 403, 10.1017/S1041610200006505 · DOI
  22. Schneider, 1996, Clinical global impressions in Alzheimer's clinical trials, Int Psychogeriatr., 8, 277, 10.1017/S1041610296002645 · DOI
  23. Schneider, 1996, Clinical global impressions in Alzheimer's clinical trials, Int Psychogeriatr., 8, 288, 10.1017/S1041610296002645 · DOI
  24. Galasko, 2005, Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease, J Int Neuropsychol Soc., 11, 446, 10.1017/S1355617705050502 · DOI
  25. Koch, 1998, Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them, Stat Med., 17, 1863, 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1863::AID-SIM989>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19980815/30)17:15/16<1863::aid-sim989>3.0.co;2-m
  26. Brodaty, 2005, Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease, Dement Geriatr Cogn Disord., 20, 120, 10.1159/000086613 · DOI
  27. Galasko, 2004, Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease, J Am Geriatr Soc., 52, 1070, 10.1111/j.1532-5415.2004.52303.x · DOI
  28. Demers, 2000, Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of functional and quality of life scales, J Geriatr Psychiatry Neurol., 13, 170, 10.1177/089198870001300402 · DOI
  29. Black, 2007, Donepezil preserves cognition and global function in patients with severe Alzheimer's disease, Neurology., 69, 459, 10.1212/01.wnl.0000266627.96040.5a · DOI · Paper page
  30. Homma, 2008, Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebocontrolled, randomized trial, Dement Geriatr Cogn Disord., 25, 399, 10.1159/000122961 · DOI
  31. Vellas, 2005, Consensus statement on dementia of Alzheimer type in the severe stage, J Nutr Health Aging., 9, 330
  32. Whitehead, 2004, Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A meta-analysis of individual patient data from randomised controlled trials, Int J Geriatr Psychiatry., 19, 624, 10.1002/gps.1133 · DOI

Cited by

See all 186

Metadata

Authors
Farlow, M. R., Salloway, S., Tariot, P. N., Yardley, J., Moline, M. L., Wang, Q., Brand-Schieber, E., Zou, H., Hsu, T., & Satlin, A.
Venue
Clinical Therapeutics
Publisher
Elsevier BV
Published
2010-07
Volume
32
Issue
7
Pages
1234-1251
ISSN
0149-2918
Cited by
186
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. https://app.cochat.ai/papers/10.1016/j.clinthera.2010.06.019
The paper
Farlow, M. R., Salloway, S., Tariot, P. N., Yardley, J., Moline, M. L., Wang, Q., Brand-Schieber, E., Zou, H., Hsu, T., & Satlin, A. (2010). Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clinical Therapeutics. https://doi.org/10.1016/j.clinthera.2010.06.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.